Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531940) titled 'Escalating Doses of Memantine in Down Syndrome (MEDS-123)' on April 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University Hospitals Cleveland Medical Center
Condition:
Down Syndrome
Intellectual Disability
Intervention:
Drug: Memantine
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: June 2026
Target Sample Size: 25
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07531940
Disclaimer: Curated ...